Amplia Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is April - March.

Millions AUD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	-7.93	-6.57	-4.5	-6.24	-3.64	-2.28
Depreciation & Amortization	0.08	0.09	0.09	0.07	0	0
Stock-Based Compensation	0.08	0.08	0.09	0.21	0.06	0.35
Other Operating Activities	-5.05	0.06	0	0	-0	0
Change in Accounts Receivable	-0.67	-0.67	-2.04	0.68	-0.83	-1.02
Change in Accounts Payable	0.13	0.13	1.25	-0.01	0	0.03
Operating Cash Flow	-13.36	-6.89	-5.13	-5.29	-4.4	-2.92
Capital Expenditures	-0.03	-0	-0	-0.02	-0.01	-0.01
Other Investing Activities	-0.05	-	-	-0.04	-0.01	-
Investing Cash Flow	-0.08	-0	-0	-0.06	-0.03	-0.01
Long-Term Debt Issued	-	-	1.47	-	2.1	-
Long-Term Debt Repaid	-	-1.55	-2.18	-0.06	-	-
Net Debt Issued (Repaid)	-0.07	-1.55	-0.71	-0.06	2.1	-
Issuance of Common Stock	40.9	17.28	0	0.02	16.27	4.06
Other Financing Activities	-2.83	-1.41	-0.06	-0.04	-1.18	-0.4
Financing Cash Flow	37.99	14.32	-0.77	-0.08	17.19	3.66
Foreign Exchange Rate Adjustments	0.05	0.05	0.03	0.08	-0	-0
Net Cash Flow	24.6	7.48	-5.87	-5.35	12.76	0.74
Free Cash Flow	-13.39	-6.89	-5.13	-5.31	-4.42	-2.92
Free Cash Flow Margin	-267.38%	-182.04%	-115.20%	-446.19%	-222.68%	-190.52%
Free Cash Flow Per Share	-0.03	-0.02	-0.03	-0.03	-0.03	-0.03
Cash Interest Paid	0.01	0.08	0.06	0.04	-	-
Cash Income Tax Paid	-	-3.18	-2.41	-1.84	-1.14	-0.57
Levered Free Cash Flow	-10.59	-4.77	-3.59	-2.99	-3.07	-2.1
Unlevered Free Cash Flow	-10.59	-4.74	-3.54	-2.95	-3.07	-2.1
Change in Working Capital	-0.53	-0.53	-0.8	0.67	-0.82	-0.99

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.